|
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical research trials and A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus clinical trial. Human subjects often receive the most effective healthcare possible for their A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus  A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
For Condition: Diabetes
Status: Completed
Sponsor(s): Hoffmann-La Roche ,
Synopsis: The objectives of the study are: To determine the dose(s) of Ro 205-2349 which, when compared to placebo, are efficacious, safe and tolerable in improving glycemic control in patients with type 2 diabetes. Doses of 5 to 20 mg/day will be studied.
Details:
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 35 Years/75 Years
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - Age 35 to 75 - Type 2 diabetes for longer than 3 months - HbA1c (glycosylated hemoglobin A1c) greater than 7.0% at screening - FPG (fasting plasma glucose) greater than 126 mg/dL at screening - BMI (body mass index) less than 40 kg/square meter Exclusion Criteria: - Type I diabetes - Type 2 diabetes patients currently treated with insulin - Type 2 diabetes patients curently or previously treated with Actos, Avandia or Rezulin - FPG (fasting plasma glucose) greater than 270 mg/dL at baseline - Impaired liver or kidney function - Triglycerides greater than 600 mg/dL - Uncontrolled hypertension - Pregnant or lactating women - Women not using adequate contraception
Total Enrollment:
Location and Contact Information:
Additional Information:
Study ID Numbers: WM16177;
Study Start Date:
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00057317
Other Diabetes Studies:
1. Clinical Trial of Footwear in Patients with Diabetes
2. Epidemiology of Hearing Loss in Diabetic and Non-Diabetic Veterans
3. A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
4. Family-Centered Diabetes Project
5. A Phase II randomized, double-blind, dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
Related Studies:
Other Diabetes Clinical Trials
Other New York Clinical Trials
Other Rochester Clinical Trials
A Phase II randomized, double-blind, placebo-controlled dose-ranging study to determine the efficacy, safety, tolerability and pharmacokinetics of Ro 205-2349 in patients with Type 2 diabetes mellitus
|
|
|
|
|
|
|
|
